Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (French)

17 February 2023

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB PrEP). The document includes prompts for national-level consideration during the guideline adaptation process.

This is the French version of the guidelines. For the English version, please click here. For the Spanish version, please click here.

Topic(s): Normative Guidance/Policies

Product(s): Cabotegravir, Dapivirine Vaginal Ring, Injectable Prep, Oral PrEP, TDF/xTC

Language(s): French

Format(s): Form/Template

Source(s): MOSAIC

Type: Document

Download

Featured Resources

External Link

Low Selection of HIV PrEP Refills at Private Pharmacies among Clients who Initiated PrEP at Public Clinics: Findings from a mixed-methods study in Kenya

This article from BMC Health Services Research describes the impact of a pilot project to permit oral PrEP users to obtain refills at private pharmacies for an additional fee.
Presentation

Nigeria National Oral PrEP Implementation Plan (2022-24) Assessment Presentation

From October 2023 to April 2024, MOSAIC supported the Federal Ministry of Health to evaluate the National Oral PrEP Implementation Plan (Jan 2022 – Jan 2024). The purpose of the evaluation was to assess the achievement of priority activities stipulated in the National Oral PrEP Implementation Plan (Jan 2022-Jan 2024) against the intended objectives. The…
Document

Nigeria National Oral PrEP Implementation Plan (2022-24) Assessment Report

From October 2023 to April 2024, MOSAIC supported the Federal Ministry of Health to evaluate the National Oral PrEP Implementation Plan (Jan 2022 – Jan 2024). The purpose of the evaluation was to assess the achievement of priority activities stipulated in the National Oral PrEP Implementation Plan (Jan 2022-Jan 2024) against the intended objectives. The…
Spreadsheet

Access Workbook for Cabotegravir for PrEP and Dapivirine Vaginal Ring

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP and the dapivirine vaginal ring (DVR) for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit product pricing, and information…
Presentation

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.
External Link

HPTN 083-02: Factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

This article from Journal of the International AIDS Society to explores the experiences of participants in the HPTN-083 trial, which evaluated safety and efficacy of cabotegravir for PrEP, including barriers to adherence and other factors that may have impacted study implementation or outcomes.
External Link

Self-reported Removal and Expulsion of the Dapivirine Vaginal Ring: Qualitative reports from female ring users and their male partners in the Ring Study (IPM 027)

This article from BMC Public Health explores participants’ and their male partners’ discussions on accidental/purposeful vaginal ring removals during The Ring Study (IPM-027 clinical trial of the one month dapvirine vaginal ring).
External Link

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled analysis from 72 global studies

This article from Clinical Infectious Diseases reviews 72 prospective studies of daily oral PrEP (TDF/FTC) to evaluate its impact on HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings.
Document

MOSAIC (Maximizing Options to Advance Informed Choice for HIV Prevention)

Short introduction to MOSAIC, a project working across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide…
Document

Access, Adherence, and Acute HIV Infections: A characterization of seroconversion with PrEP in Eswatini

This poster, presented at the INTEREST conference in Cotonou, Benin in 2024, outlines characteristics of seroconversions by women using oral PrEP or the dapivirine vaginal ring in Eswatini.